Polypharmacy associated with medical tourism: a critique on drug therapy

Pennings G. Ethics without boundaries: medical tourism. In: Ashcroft RE, Dawson A, Draper H, McMillan JR, editors. Principles of health care ethics, 2nd edn. West Sussex, England: Wiley; 2007. Print ISBN: 978 047002 713 4; online ISBN 978 047051 054 4. Horowitz MD, Rosensweig J, Jones CA. Medical trourism: globalization of the healthcare marketplace. Med Gen Med. 2007;9:33. Good CB. Polypharmacy in elderly patients with diabetes. Diabetes Spectr. 2002;15:240–8. Lee RD. Polypharmacy: a case report and new protocol for management. J Am Board Fam Pract. 1998;11:140–4. Holstein A, Egberts EH. Risk of hypoglycemia with oral antidiabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003;111:405–14. British National Formulary (BNF)-55: March 2008. BMJ Group and RPS Publishing 2008. Print ISBN: 978 085369 776 3. Martindale. The complete drug reference. Thirty-third edition (ed) Sweetman SC. London: Chicago Pharmaceutical Press; 2002. Print ISBN 0 85369 499 0. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 18: CD003639. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, et al. Thiazolidinedione use, fluid retention and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256–63. Starner CI, Schafer JA, Heaton AH, Gleason PP. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk warning events. J Manag Care Pharm. 2007;14:523–31. American Diabetes Association. Position statement. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004; 27 (suppl 1): S68–71. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atovastatin in adults with hypercholesterolemia. Am J Cardiol. 2004;93:1487–94. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on pharmacokinetics and drug interactions. Circulation. 2004;109(23 Suppl 1):11150–7. Robin SJ. Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans affairs high-density lipoprotein interaction trial. Am J Cardiol. 2001;88:19N–23N. American Diabetes Association. Position statement. Diabetic nephropathy. Diabetes Care. 2002; 25(Suppl 1): S85–9. Jensen TS, Backonja M, Jimenez SH, Tesfaye S, Valensi P, Ziegler D. New perspective on the management of diabetic peripheral neuropathic pain. Diabetes Vasc Dis Res. 2006;3:108–19. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Eng J Med. 1992;326:1287–8. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain. How far have we came? Diabetes Care. 2008;31(Suppl 2):S255–61.